SCHOLAR ROCK HOLDING CORP (SRRK)

3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains

These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly.

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q4 2023

SRRK stock results show that Scholar Rock Holding missed analyst estimates for earnings per share the fourth quarter of 2023.

SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Scholar Rock Holding (NASDAQ:SRRK) just reported results for the fourth quarter...

Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Commit To Buy Scholar Rock Holding At $10, Earn 14.3% Annualized Using Options

Scholar Rock to Participate in Upcoming Investor Conferences

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439 in Obesity at Keystone Symposia

Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock Provides Corporate Update and Highlights Priorities for 2024

3 Biotech Stocks at the Forefront of the Quest for Eternal Youth

Biotech stocks targeting longevity could uncover the fountain of youth in coming years, offering a prime investment opportunity today.

Scholar Rock to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock Reports Third Quarter 2023 Financial Results and Highlights Business Progress

Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued Tolerability

Scholar Rock to Participate in Upcoming Investor Conferences

Jefferies upgrades Scholar Rock to buy; cites SMA, obesity drug assets (NASDAQ:SRRK)

Jefferies upgrades Scholar Rock to buy based in part on the potential for its spinal muscular atrophy drug candidate. Read more here.

Scholar Rock to Present Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 38th Annual Meeting

Scholar Rock Holding says Invus Public Equities buys 2.2M shares (NASDAQ:SRRK)

Invus Public Equities purchases 2.2M shares of Scholar Rock Holding at $6.9-$8.5 per share, boosting the company's stock price by 2.54% to $8.47.

Scholar Rock Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

Why Scholar Rock Holding Stock Soared Today

The market celebrated Scholar Rock's upsized stock offering and plans to advance development of a new obesity treatment. Here's what investors need to know.

Scholar Rock prices upsized $85M offering (NASDAQ:SRRK)

Scholar Rock has priced an upsized public offering, expecting to raise approximately $85M.

Scholar Rock Announces Pricing of Upsized Public Offering of Common Stock

Scholar Rock plans for $75M stock offering (NASDAQ:SRRK)

Invest in your financial future with expert insights from our financial writer.